Dewpoint Therapeutics

OverviewSuggest Edit

Dewpoint Therapeutics is a company focused on condensate biology. It uses biomolecular condensates to develop drugs for neurodegeneration, cancer, inflammation, infectious diseases, metabolic diseases, and rare genetic disorders.

TypePrivate
Founded2018
HQCambridge, US
Websitedewpointx.com

Latest Updates

Employees (est.) (Apr 2020)31(+4%)

Dewpoint Therapeutics Office Locations

Dewpoint Therapeutics has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square, Building 200, Suite 001
Show all (1)

Dewpoint Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Dewpoint Therapeutics total Funding

$60 m

Dewpoint Therapeutics latest funding size

$60 m

Time since last funding

a year ago

Dewpoint Therapeutics investors

Dewpoint Therapeutics's latest funding round in January 2019 was reported to be $60 m. In total, Dewpoint Therapeutics has raised $60 m
Show all financial metrics

Dewpoint Therapeutics Online and Social Media Presence

Embed Graph

Dewpoint Therapeutics Blogs

Dewpoint Scientific Founder Richard Young Elected to the National Academy of Medicine

WHITEHEAD INSTITUTE MEMBER RICHARD YOUNG ELECTED TO NATIONAL ACADEMY OF MEDICINE Whitehead Institute Member Richard A. Young has been elected to the United States National Academy of Medicine (NAM). Along with the National Academy of Sciences (NAS) and National Academy of Engineering, the NAM provid…

Signaling Factor Seeking Gene

Cambridge, MA — During embryonic development, stem cells begin to take on specific identities, becoming distinct cell types with specialized characteristics and functions, in order to form the diverse organs and systems in our bodies. Cells rely on two main classes of regulators to define and mainta…

Fast-Growing Dewpoint Therapeutics Honored by FierceBiotech

Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has been recognized by FierceBiotech as one of 2019’s most promising private biotechs. “This year has seen unrivalled scientific talent in the early-stage life sciences world and …

Dynamic Enhancer DNA Methylation as Basis for Transcriptional and Cellular Heterogeneity of ESCs

Variable levels of DNA methylation have been reported at tissue-specific differential methylation regions (DMRs) overlapping enhancers, including super-enhancers (SEs) associated with key cell identity genes, but the mechanisms responsible for this intriguing behavior are not well understood. We use…

Study furthers radically new view of gene control

In recent years, MIT scientists have developed a new model for how key genes are controlled that suggests the cellular machinery that transcribes DNA into RNA forms specialized droplets called condensates. These droplets occur only at certain sites on the genome, helping to determine which genes are…

Enhancer features that drive formation of transcriptional condensates

Enhancers are DNA elements that are bound by transcription factors (TFs), which recruit coactivators and the transcriptional machinery to genes. Phase-separated condensates of TFs and coactivators have been implicated in assembling the transcription machinery at particular enhancers, yet the role of…
Show more

Dewpoint Therapeutics Frequently Asked Questions

  • When was Dewpoint Therapeutics founded?

    Dewpoint Therapeutics was founded in 2018.

  • How many employees does Dewpoint Therapeutics have?

    Dewpoint Therapeutics has 31 employees.

  • Who are Dewpoint Therapeutics competitors?

    Competitors of Dewpoint Therapeutics include ReViral, Sosei Heptares and Seres Therapeutics.

  • Where is Dewpoint Therapeutics headquarters?

    Dewpoint Therapeutics headquarters is located at One Kendall Square, Building 200, Suite 001, Cambridge.

  • Where are Dewpoint Therapeutics offices?

    Dewpoint Therapeutics has an office in Cambridge.

  • How many offices does Dewpoint Therapeutics have?

    Dewpoint Therapeutics has 1 office.